Guillermo Suay - Publications

First-line osimertinib in advanced EGFR-mutated NSCLC: real-world outcomes, clinicogenomic correlates, and oligoprogression management in a multicenter Spanish cohort.

Journal: ESMO real world data and digital oncology

Published: July 01, 2026

Characteristics and clinical outcomes of a nationwide cohort of patients with small cell lung cancer following first-line treatment: Real-world evidence.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 17, 2026

Biomarker landscape in advanced NSCLC: insights from a national prospective registry.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 23, 2025

Role of miRNAs as epigenetic regulators of immune checkpoints in lung cancer immunity.

Journal: International review of cell and molecular biology

Published: January 26, 2025

Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations.

Journal: Cancer letters

Published: September 05, 2024

A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: August 20, 2024

Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 06, 2024